Aurobindo Pharma Limited — Updates, 13-05-2025: Press Release

Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, secured UK MHRA approval for Zefylti®, its filgrastim biosimilar, following prior EU approval. This is CuraTeQ’s second MHRA-approved biosimilar, enhancing Aurobindo’s foothold in oncology and immunology biosimilars. With 14 biosimilars in development and integrated production capabilities, Aurobindo is positioned for growth in high-potential biosimilars markets.